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Edited by Jesus AvilaAbstract Neurosteroids are known as allosteric modulators of
ionotropic c-aminobutyric acid (GABA) receptors. Here, we
investigated sites of positive allosteric modulation by allotetra-
hydrodeoxycorticosterone (5a-THDOC) at GABA receptors
using the technique of chimeragenesis and the Xenopus oocyte
expression system. Our ﬁndings have demonstrated that the
region from transmembrane segment (TM) 4 to the C-terminus
of the GABAA receptor a1 subunit is crucial for the action of 5a-
THDOC, but insuﬃcient for the action of another neurosteroid
allopregnanolone, suggesting that a speciﬁc region critical for
neurosteroid action at GABA receptors exists in the domain
between TM4 and the C-terminus of GABA receptor subunits.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In the mammalian central nervous system (CNS), fast
inhibitory synaptic transmission is mediated mainly by the c-
aminobutyric acidA (GABAA) receptor, a member of the li-
gand-gated ion channel superfamily, whose members include
glycine receptors, nicotinic acetylcholine (nACh) receptors, and
serotonin type 3 receptors [1]. To date, a number of clinically
important drugs such as benzodiazepines, barbiturates, and
volatile and intravenous anesthetics are known to act as posi-
tive allosteric modulators of GABAA receptors, and their sites
of actions on GABAA receptor subunits have been investigated
at the molecular level using site-directed mutagenesis [2].
Neurosteroids (neuroactive steroids) are synthesized de novo
in the CNS and may alter neuronal excitability via the cell
surface through an interaction with speciﬁc neurotransmitter
receptors [3]. Many studies have demonstrated that neuros-
teroids positively and negatively modulate the function of
members of the ligand-gated ion channel superfamily [4], and
most of those studies have focused on the positive allosteric* Corresponding author. Fax: +81-93-601-6264.
E-mail address: susumu@med.uoeh-u.ac.jp (S. Ueno).
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doi:10.1016/j.febslet.2004.04.030actions at GABAA receptors. It has been suggested that, as for
other allosteric modulators, there may be a speciﬁc region for
neurosteroid binding on the GABAA receptor molecule, a
theory supported by previous reports that the interaction of
neurosteroids with the GABAA receptor is dependent on
subunit composition [5,6].
The GABAC receptor, another type of ionotropic GABA
receptor, is composed of GABA q1 and/or q2 subunits as a
pentamer. This receptor, which ismainly expressed in the retina,
has channel function and drug sensitivity properties diﬀerent
from the GABAA receptor [7]. In particular, the GABAC re-
ceptor has been thought to be insensitive tomost potentiators of
GABAA receptors, including neurosteroids. In a recent study,
however, allotetrahydrodeoxycorticosterone (5a-THDOC), a
metabolite of corticosterone that produces anticonvulsant [8],
anxiolytic [9–11], and sleep-modulating eﬀects [12,13] in vivo
due to a positive allosteric modulation of GABAA receptor
function, has been demonstrated to potentiate the GABA-in-
duced current in homomeric GABA q1 receptors at micromolar
concentrations [14]. Although the concentration of neurosteroid
used in that study was higher than that used in previous studies
of GABAA receptors, this result suggests that the GABAC re-
ceptor is alsomodulated by neurosteroids, raising the possibility
that there may be a common region of theGABAA andGABAC
receptor subunits speciﬁc for the action of 5a-THDOC.
The sites of neurosteroid action on GABAA receptor sub-
units remain to be clariﬁed at the amino acid level. In an at-
tempt to determine these sites, chimeric receptor proteins
comprised of GABAA receptor b subunits and the glycine re-
ceptor a subunit were constructed previously [15], based on
evidence that the homomeric glycine a receptor is insensitive to
several positive allosteric modulators of GABAA receptors,
including neurosteroids [16,17], whereas the homomeric
GABAA b receptor can be modulated by a neurosteroid an-
esthetic, alphaxalone [18]. This approach, however, needs
further reﬁnement, because the homomeric GABAA b receptor
has unusual channel properties that may complicate investi-
gation of the action of neurosteroids using chimeric GABAA-
receptor-b/glycine-receptor-a subunit proteins.
In the present study, we ﬁrst investigated the action of 5a-
THDOC, applying the approach of expressing homomeric re-
ceptors composed of chimeric proteins containing the GABA
receptor q and glycine receptor a subunits. If critical regions ofblished by Elsevier B.V. All rights reserved.
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ing regions of the GABAA receptor subunits could also be
demonstrated to be important for the action of neurosteroids.Fig. 1. (A) Sample tracings obtained from a single Xenopus oocyte
expressing wild-type GABA q1 or glycine a1 (Glya1) receptors
homomerically demonstrate the eﬀects of 5a-THDOC (20 lM) on
currents induced by the EC of GABA (GA) or glycine (Gly). 5a-2. Materials and methods
2.1. Materials
Adult female Xenopus laevis were obtained from Seac Yoshitomi
(Fukuoka, Japan); GABA, 5a-THDOC, allopregnanolone, collage-
nase type 1A, penicillin–streptomycin solution, and gentamicin solu-
tion were from Sigma Chemical Co. (St. Louis, MO); glycine was from
Nacalai Tesque (Kyoto, Japan). All other chemicals used were of re-
agent grade. Our study was reviewed and approved by the Ethics
Committee on Animal Experiments and Care of the University of
Occupational and Environmental Health.
2.2. Construction of chimeric cDNAs
Chimeras C1 and C2 were constructed by methods described pre-
viously [19]. The C1 chimera was composed of the human glycine a1
(Glya1) receptor subunit sequence from the N-terminus to the junction
site in transmembrane segment (TM) 3 and the human GABA receptor
q1 subunit sequence from the junction site to the C-terminus. C2 was
the converse chimera of C1, consisting of the GABA receptor q1
subunit sequence from the N-terminus to the junction site and the
Glya1 receptor subunit from the junction site to the C-terminus. To
construct other chimeras, the QuikChange Site-directed Mutagenesis
Kit (Stratagene, La Jolla, CA) was used to introduce a ClaI restriction
site into the cDNA sequence encoding the conserved amino acid se-
quence ‘‘ID’’ close to the beginning of TM4 in the human GABA
receptor q1, human Glya1 receptor, and human GABAA receptor a1
subunit (see Fig. 3), respectively, as subcloned into a modiﬁed pBK-
CMV vector [20]. These chimeras have the Glya1 receptor subunit
sequence from the N-terminus to the junction sites located just before
TM4, and the GABA receptor q1 (C8) or the GABAA receptor a1 (C9)
subunit sequence from the junction site to the C-terminus. All point
mutations were veriﬁed by double-stranded DNA sequencing.
2.3. Expression of chimeric receptors in Xenopus oocytes and
electrophysiological recordings
Stage V and VI oocytes from adult female X. laevis were isolated,
injected with 1.5–2.0 ng cDNA of wild-type human GABA q1, human
Glya1, humanGABAA a1b2c2S or chimeric receptor subunit, and two-
electrode voltage-clamp recordings were performed as described
previously [21,22]. Oocytes were voltage-clamped at )70 mV using the
OC-725C Oocyte Clamp Ampliﬁer (Warner Instruments, Inc., Ham-
den, CT), and currents were digitally recorded with PowerLab/200 and
Chart software (ADInstruments, Grand Junction, CO). Glycine or
GABA was applied for 30–180 s to obtain the maximum (peak) current
used as a measure of drug response. We tested the capacity of neuros-
teroids to enhance the eﬀect of the glycine/GABA concentration that
produced 10% of themaximal eﬀect (EC10) of glycine/GABA. This EC10
was determined individually for each oocyte. We used 1–3 mM glycine/
GABA to produce a maximal current. Neurosteroids were ﬁrst dis-
solved in dimethyl sulfoxide (DMSO), then diluted in modiﬁed Barth’s
saline before use at a ﬁnal DMSO concentration not exceeding 0.05%,
which had no eﬀect on agonist-evoked responses (data not shown).
Oocytes were perfused with neurosteroids for 2 min before coapplica-
tion of glycine/GABA to allow for complete equilibration of the oocytes
with neurosteroids. In all cases, a 15–20-min washout period was al-
lowed following application of the neurosteroid/agonist solutions.
2.4. Data analysis
Each data point represents the meanS.E.M. from 4 to 38 oocytes
obtained from at least two diﬀerent frogs.
10
THDOC was preapplied for 2 min before co-application of agonists.
(B) Schematic representations show the construction of the wild-type
GABA receptor q1 (open bars) or the Glya1 receptor subunit (closed
bars), and the C1 or C2 chimeric subunit, respectively, which have
been described previously [19]. (C) Sample tracings obtained from a
single Xenopus oocyte expressing C1 or C2 chimeric receptors homo-
merically demonstrate the eﬀects of 5a-THDOC (20 lM) on currents
induced by the EC10 of GABA (GA) or glycine (Gly). 5a-THDOC was
preapplied for 2 min before co-application of agonists.3. Results and discussion
3.1. The action of 5a-THDOC on C1 and C2 chimeric receptors
expressed in Xenopus oocytes
We ﬁrst studied the eﬀect of micromolar concentrations of
5a-THDOC on GABAC and glycine receptor function. Forwild-type GABA q1 receptors expressed in Xenopus oocytes,
20 lM 5a-THDOC produced up to about 110% potentiation
of the current induced by the EC10 of GABA (Figs. 1A and 2),
which is consistent with the evidence demonstrated previously
[14]. In contrast, at wild-type Glya1 receptors 5a-THDOC did
not show much potentiation (up to about 45%) of the current
induced by the EC10 of glycine (Figs. 1A and 2). Since both
GABA q1 and Glya1 receptor subunits are members of the
ligand-gated ion channel superfamily, share similar structure,
and form functional homomeric receptors, construction of
chimeric proteins between GABA q1 and Glya1 subunits
should be useful for the investigation of sites of 5a-THDOC
action.
Therefore, to examine which regions are critical for the en-
hancing eﬀect of 5a-THDOC, we used chimeras C1 and C2,
which were constructed previously ([19]; Fig. 1B). Both are
functional when expressed homomerically in oocytes and ac-
tivated by glycine and GABA, respectively. At C1, 20 lM of
5a-THDOC produced about 180% potentiation of the EC10
glycine-induced current (Figs. 1C and 2). The converse chi-
mera C2, however, produced only as much potentiation as
observed with the wild-type Glya1 receptor (Figs. 1C and 2).
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THDOC at wild-type and chimeric receptors. Signiﬁcant
potentiation was not observed at wild-type Glya1 and C2
chimeric receptors, but much greater potentiation was pro-
duced at wild-type GABA q1 and C1 chimeric receptors
(Fig. 2). These results suggest that the region from TM3 to the
C-terminus of the GABA q1 subunit contains residues critical
for the enhancing eﬀect of 5a-THDOC.
3.2. Construction of new chimeric subunit cDNAs and their
functional expression in Xenopus oocytes
We next constructed new chimeras, C8 and C9, to investi-
gate in more detail the region critical for the action of 5a-
THDOC (Fig. 3). We hypothesized that such action of
5a-THDOC, that is, a non-genomic eﬀect of 5a-THDOC on
GABA receptor function, would involve in the extracellular
segments including TM4, rather than the intracellular seg-
ments of the receptor subunits. Therefore, we constructed
those chimeras whose junction site is located close to the be-
ginning of TM4 of the subunits. The cDNAs of those chimeras
were individually injected into oocytes and tested with glycine
to assay for functional expression. Although both chimeras
have extracellular glycine-binding domains, no signiﬁcant0 5 10 15 20
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Fig. 2. The eﬀects of various concentrations of 5a-THDOC on GABA-
evoked responses at wild-type GABA q1 (open circles) and C2
chimeric receptors (closed squares), and glycine-evoked responses at
wild-type Glya1 (closed circles) and C1 chimeric receptors (open
squares) expressed in Xenopus oocytes. The values of the EC10 con-
centrations used in this study were as follows: 0.34 0.02 lM of
GABA for wild-type GABA q1 receptor, 28 4 lM of glycine for
wild-type Glya1 receptor, 103 6 lM of glycine for C1, and
0.40 0.01 lM of GABA for C2. The EC10 of GABA for C2 is sig-
niﬁcantly diﬀerent (P < 0:01, using unpaired, two-tailed t-tests) from
that for wild-type GABA q1 receptor, and the EC10 of glycine for C1 is
also signiﬁcantly diﬀerent (P < 0:001, using unpaired, two-tailed t-
tests) from that for wild-type Glya1 receptor. All values are presented
as meansS.E.M. from 5 to 11 oocytes. P < 0:01 and #P < 0:001,
compared to wild-type Glya1 receptor, and yP < 0:001 compared to
wild-type GABA q1 receptors using unpaired, two-tailed t-tests.glycine-evoked response was obtained from oocytes expressing
C8 chimeric receptors (Fig. 4). This could be because this
chimeric receptor protein could not, if homomerically ex-
pressed, form a functional chloride channel or be inserted into
the plasma membrane. Since the GABAA receptor is a main
target for the actions of neurosteroids in vivo, the goal of the
present study was to determine the sites of neurosteroid action
on GABAA receptor subunits as well as GABA q1 receptors.
Therefore, we studied the chimera C9, which had the same
construct from the N-terminus to the junction site as C8 but
had the GABAA receptor a1 subunit from the junction site to
the C-terminus. C9 chimeric receptors expressed in oocytes
produced an inward current with glycine, with a fast peak
time, similar to the one for the wild-type Glya1 receptor
(Fig. 4A, inset), although the EC10 glycine concentration was
higher (188 20 lM), compared to the wild-type receptor
(103 6 lM).
3.3. The action of 5a-THDOC and allopregnanolone on C9
chimeric receptors
Using an EC10 of glycine, we obtained about 140% poten-
tiation of the glycine-evoked response at C9 chimeric receptors
(Fig. 4A). These results suggest that the region from TM4 to
the C-terminus of the GABAA receptor a1 subunit is critical
for the action of 5a-THDOC. The corresponding region of the
GABA q1 receptor subunit could also be involved in the action
of 5a-THDOC, although we did not obtain the results from
the chimeric C8 receptor. To our knowledge, this is the ﬁrst
evidence that the region from TM4 to the C-terminus of the
GABA receptor subunit is important for neurosteroid action.
We then tested the ability of allopregnanolone, a proges-
terone metabolite and a potent positive modulator of GABAA
receptors (Fig. 4B, inset), to potentiate the glycine response of
the C9 chimera. 20 lM of allopregnanolone, however, pro-
duced only 33 12% potentiation of the glycine-evoked cur-
rents at this chimera, which was similar to that obtained from
the wild-type Glya1 receptor (Fig. 4B), suggesting that the
region from TM4 to the C-terminus of the GABAA receptor a
subunit may not be suﬃcient for the action of allopregnano-
lone. This is consistent with the evidence that alphaxalone, a
neurosteroid anesthetic, may act on GABAA receptors via the
N-terminal side of TM2 of the a subunit [15] or a residue lo-
cated in TM1 of the b subunit [23], since alphaxalone is a
synthetic analog of allopregnanolone and has similar eﬃcacy
at GABAA receptors [24]. Moreover, as demonstrated in the
present study (Fig. 4B) as well as previous work [14], allo-
pregnanolone and alphaxalone do not enhance GABA q1 re-
ceptor function as much as 5a-THDOC, suggesting that
allopregnanolone and alphaxalone may also act on GABAA
and GABA q1 receptors via a mechanism diﬀerent from 5a-
THDOC. Further investigation is required to determine the
region critical for the actions of allopregnanolone and al-
phaxalone at GABAA and GABAC receptors.
3.4. A possible interaction of the region from TM4 to the
C-terminus of GABA receptor subunits with neurosteroids
The region from TM4 to the C-terminus of the subunit of
the ligand-gated ion channel superfamily has been demon-
strated to be involved in gating and allosteric modulation of
channel function. For example, TM4 may be involved in
aﬃnity for acetylcholine and channel gating in mouse nico-
tinic and Torpedo acetylcholine receptors [25,26]. Moreover,
Fig. 4. The eﬀects of 20 lM of 5a-THDOC (A) and allopregnanolone (B) on
Glya1 (closed bar), and C9 chimeric receptors (hatched bar) expressed in Xe
oocytes expressing C8 chimeric receptors (asterisks). The EC10 concentrat
(P < 0:001, using unpaired, two-tailed t-tests) from that for wild-type Glya
oocytes. The data in (A) for the GABA q1 and Glya1 receptors are from Fig
two-tailed t-tests. Inset in (A), sample tracings obtained from a single oocyte e
of 5a-THDOC on currents induced by the EC10 of glycine (Gly). 5a-THDO
Inset in (B), the eﬀects of 5a-THDOC and allopregnanolone on GABA-indu
concentration of both neurosteroids used is 1 lM. All values are presented
Fig. 3. Schematic representations demonstrate the construction of
chimeras C8 and C9. The construction of the wild-type human GABA
receptor q1 (open bars), human Glya1 receptor (closed bars), and
human GABAA receptor a1 (hatched bars) subunit (upper panel), and
amino acid sequences around the TM4 region (including the C-ter-
minus) of those subunits are shown, respectively (middle panel). As-
terisks indicate the conserved amino acids among those subunits. To
construct C8 and C9 chimeras, a unique restriction enzyme site was
introduced into the cDNA sequence encoding the conserved amino
acid sequence ‘‘ID’’ close to the beginning of TM4. The constructions
of the resultant chimeric subunits are also shown schematically (lower
panel).
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the extracellular end of TM4 of the GABAA receptor a subunit
may be important for the positive modulatory eﬀects of in-
haled anesthetics. Interestingly, it has been suggested that the
C-terminal tail of the neuronal nACh receptor a4 subunit is
required for potentiation by estradiol, acting as a steroid-
binding site [28,29]. This may strongly support our results,
suggesting that the corresponding regions of the GABAA and
GABAC receptor subunits may also act as steroid-binding
sites. Estradiol, however, has not been reported to be an al-
losteric modulator of GABAA and GABAC receptors, and not
many amino acid residues are conserved in the TM4-to-car-
boxyl terminus region between the GABAA/GABA q1 recep-
tor and neuronal nACh receptor subunits. Therefore, further
studies are required to investigate if, in the ligand-gated ion
channel superfamily, the TM4-to-carboxyl terminus regions of
the receptor subunits are involved in the potency and eﬃcacy
of diﬀerent neurosteroids in the allosteric modulation of
receptor function.
In conclusion, we demonstrate that there are regions speciﬁc
for the action of neurosteroids atGABAA andGABAC receptor
subunits and that one candidatemaybe located fromTM4 to the
C-terminus in theGABAA receptor a subunit. Our observations
should help provide a better understanding of a structure–
function relationship between neurosteroids and receptor sub-
units of members of the ligand-gated ion channel superfamily.GABA or glycine-evoked responses in wild-type GABA q1 (open bar),
nopus oocytes. Note that no glycine-evoked current was obtained from
ion of glycine for C9 is 188 20 lM, which is signiﬁcantly diﬀerent
1 receptor. All values are presented as means S.E.M. from 4 to 12
. 2. #P < 0:001, compared to wild-type Glya1 receptor using unpaired,
xpressing C9 chimeric receptors homomerically demonstrate the eﬀects
C (20 lM) was preapplied for 2 min before co-application of glycine.
ced responses in wild-type GABAA a1b2c2S receptors. Note that the
as meansS.E.M. from ﬁve oocytes.
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